Sarepta Therapeutics, Inc. SRPT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $730.8M-1.9% | $442.93M— | $399.36M-14.5% | $611.09M+68.4% | $744.86M+80.2% | ||
| $330.96M+174% | -$282.85M-278% | -$179.95M-635% | —— | -$447.51M-1,339% | ||
| 45.3%+105pp | -63.9%— | -45.1%-52.3pp | —— | -60.1%-68.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Sarepta Therapeutics, Inc.'s revenue?
- Sarepta Therapeutics, Inc. (SRPT) generated $2.2B in revenue over the trailing twelve months, up 9.8% year over year.
- Is Sarepta Therapeutics, Inc. profitable?
- Sarepta Therapeutics, Inc. is not currently profitable: it reported a net loss of $579.3M over the trailing twelve months, a 4.6% net margin.
- Where does Sarepta Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
